Market news

uniQure's BLA for AMT-130 is anchored on robust 36-month data, with the FDA signaling willingness to review. Click to read more about the Buy rating for QURE.

uniQure N.V. (NASDAQ:QURE) stock is trading lower on Tuesday after the company shared mixed long-term data from ongoing Phase 1/2 clinical studies evaluating ifezuntirgene inilparvovec for Huntington’s disease. 36-Month Clinical Results And BLA Pathway In the 36-month analysis, high-dose patients demonstrated an 80% slowing of disease progression on the Composite Unified Huntington’s Disease Rating Scale (cUHDRS) and a 67% slowing on Total Functional Capacity (TFC). cUHDRS is a specialized scori

uniQure announced long-term trial results for its Huntington's gene therapy, showing slowed disease progression at 36 and 48 months.

Uniqure stock crashed Tuesday on a disappointing four-year update for its gene therapy in patients with Huntington's disease.

ClearPoint Neuro (NASDAQ:CLPT) shares fell 24% on Tuesday following updated clinical trial results from partner uniQure N. V.

UniQure (QURE) said Tuesday additional data from its ongoing phase 1/2 studies of AMT-130 in Hunting

uniQure (QURE) stock plunges as new trial data for gene therapy candidate AMT-130 in Huntington’s disease disappoint investors. Read more here.

uniQure N.V. (NASDAQ:QURE) submitted a biologics license application, or BLA, to the U.S. Food and Drug Administration for accelerated approval of ifezuntirgene inilparvovec, formerly AMT-130, in Huntington’s disease. uniQure N.V. (NASDAQ:QURE) also requested priority review, which would provide a six-month review cycle after the FDA completes its 60-day filing review if granted. The application’s clinical-efficacy […]

After a very large three year gain in uniQure’s share price, the stock now screens as overvalued on market multiples and carries a mixed overall value score rather than a clear bargain signal. The recent run and the current valuation checks give investors a more finely balanced picture. Over the past three years, uniQure has returned very close to 7x for shareholders, which places extra focus on how much of the company’s future potential is already priced in. The recent Biologics License...

QURE seeks accelerated FDA approval for AMT-130, with Priority Review and a U.K. filing adding momentum to its regulatory push.

Detailed price information for Mckesson Corp (MCK-N) from The Globe and Mail including charting and trades.

Uniqure fell Wednesday after asking the FDA to approve its gene therapy.

uniQure announced it had submitted a Biologics License Application to the FDA seeking accelerated approval of ifezuntirgene inilparvovec, or AMT-130, for Huntington’s disease.

uniQure (QURE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Detailed price information for Uniqure N.V. (QURE-Q) from The Globe and Mail including charting and trades.

Detailed price information for Uniqure N.V. (QURE-Q) from The Globe and Mail including charting and trades.

uniQure posts a wider Q2 2026 loss as revenues missed estimates, but regulatory progress for AMT-130 and a cash runway into 2030 keep its pipeline in focus.

uniQure (QURE) delivered earnings and revenue surprises of -50.62% and -17.15%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

uniQure NV (QURE) reports steady revenue growth and regulatory progress, while navigating high R&D expenses and operational hurdles.

uniQure (NASDAQ:QURE) said it has aligned with the U.S. Food and Drug Administration on a potential accelerated-approval pathway for AMT-130, its investigational gene therapy for Huntington's disease, and remains on track to submit a biologics license application in the third quarter of 2026. Chief

~ U.S. and U.K. regulatory submissions for AMT-130 for Huntington’s disease on track as planned for the third quarter of 2026 ~ ~ Topline four-year data from the Phase I/II study of AMT-130 expected in September 2026 ~ ~ Reported data from the first cohort in the Phase I/IIa trial of AMT-260 for refractory mesial temporal lobe epilepsy showed early biological signals of therapeutic activity and a favorable safety profile ~ ~ Strengthened financial position with $259 million follow-on offering, e

At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life.

UniQure (QURE) reported a Q2 net loss Wednesday of $1.22 per diluted share, widening from a loss of

If approved, uniQure’s AMT-130 would be the first disease-modifying treatment for the inherited neurodegenerative disorder.

~ uniQure to host earnings call on Wednesday, July 29, 2026 at 8:30 a.m. ET ~LEXINGTON, Mass. and AMSTERDAM, July 22, 2026 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs will report second quarter 2026 financial results before market open on Wednesday, July 29, 2026. Management will then host a conference call at 8:30 a.m. ET. The event will be webcast under the Events & Presentations secti

uniQure’s stock has delivered a very large 301.7% return over the past three years. However, on Simply Wall St’s checks it still screens as expensive overall, with a low value score and market multiples that lean toward an overvalued verdict. Over the last three years, uniQure has returned 301.7%, which puts extra focus on whether recent gains leave enough room for mistakes in the story from here. For a research stage biotech like uniQure, future cash needs and the timing of potential...